Insider · CIK 0001914523

Ogden Christopher

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001914523

Forms 4 and 5

Insider transactions

33 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-15	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,624 sh	$3.05	−$4,953.2	295,324
2026-03-17	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−19.3K sh	$6.42	−$124K	296,948
2026-02-02	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+90K sh	—	—	316,271
2026-02-02	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+325K sh	—	—	325,000
2025-09-26	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+78.3K sh	—	—	78,250
2025-09-26	CTMXCytomX Therapeutics, Inc. · Performance Stock Units (PSUs)A Award	Chief Financial Officer	AAward	+39.2K sh	—	—	39,150
2025-06-16	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−10.6K sh	$2.69	−$28.5K	226,271
2025-06-13	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,641 sh	$2.95	−$4,841.442	199,385
2025-06-13	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+37.5K sh	—	—	236,885
2025-06-13	CTMXCytomX Therapeutics, Inc. · Performance Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−37.5K sh	—	—	0
2025-03-18	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−8,551 sh	$0.60	−$5,122.049	201,026
2025-02-04	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+44K sh	—	—	152,077
2025-02-04	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+57.5K sh	—	—	209,577
2025-02-04	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+225K sh	—	—	225,000
2025-02-04	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+115K sh	—	—	115,000
2024-08-20	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,875 sh	—	—	110,061
2024-08-20	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,984 sh	$1.23	−$2,438.534	108,077
2024-08-20	CTMXCytomX Therapeutics, Inc. · Performance Stock Units (PSUs)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,875 sh	—	—	0
2024-06-12	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+17.5K sh	—	—	103,186
2024-06-12	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2024-03-19	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,971 sh	$2.09	−$6,196.021	85,686
2024-01-18	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+40K sh	—	—	88,657
2024-01-18	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+154K sh	—	—	154,000
2024-01-18	CTMXCytomX Therapeutics, Inc. · Performance Stock Units (PSUs)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2023-12-20	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,990 sh	$1.38	−$2,747.394	48,657
2023-12-17	CTMXCytomX Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,875 sh	—	—	50,647
2023-12-17	CTMXCytomX Therapeutics, Inc. · Performance Stock Units (PSUs)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,875 sh	—	—	6,875
2023-03-16	CTMXCytomX Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−516 sh	$1.98	−$1,021.319	37,772
2023-02-02	CTMXCytomX Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+25K sh	—	—	38,288
2023-02-02	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2023-02-02	CTMXCytomX Therapeutics, Inc. · Performance Stock Units (PSUs)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2022-08-10	CTMXCytomX Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+82.5K sh	—	—	82,500
2022-08-10	CTMXCytomX Therapeutics, Inc. · Performance Stock Units (PSUs)A Award	Chief Financial Officer	AAward	+13.8K sh	—	—	13,750

Recent filings

Accepted (ET)
Jun 174
Ogden Christopher0001610717-26-000229
SEC(opens sec.gov)
Mar 194
Ogden Christopher0001610717-26-000122
SEC(opens sec.gov)
Feb 44
Ogden Christopher0001610717-26-000040
SEC(opens sec.gov)
Sep 304
Ogden Christopher0001610717-25-000355
SEC(opens sec.gov)
Jun 174
Ogden Christopher0001610717-25-000236
SEC(opens sec.gov)
Mar 204
Ogden Christopher0001610717-25-000085
SEC(opens sec.gov)
Feb 64
Ogden Christopher0001610717-25-000017
SEC(opens sec.gov)
Aug 224
Ogden Christopher0001610717-24-000433
SEC(opens sec.gov)
Jun 144
Ogden Christopher0001610717-24-000339
SEC(opens sec.gov)

Companies

CytomX Therapeutics, Inc.Chief Financial OfficerCTMX

Address

C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400

SOUTH SAN FRANCISCO, CA, 94080